Prevalence of Anti-HAV IgG Antibodies in the Population of the Łódź Macroregion by Age Group

• Autorzy: Henrykowska Gabriela , Kotecka Kornelia , Jabłkowska Aleksandra , Buczyński Andrzej , Woźny Joanna

Identyfikatory

DOI

10.2478/phr-2021-0017

Warianty tytułu

PL

Występowania przeciwciał anti-HAV IgG w populacji makroregionu łódzkiego w zależności od wieku

• Języki publikacji: EN PL

Abstrakty

EN

Over the last several decades, a gradual decrease in the incidence of hepatitis A and an increase in the population of non-immune people, especially in the group of young people have been observed in Poland. The aim of this study was to assess of the presence of specific anti-hepatitis A virus IgG class antibodies (anti-HAV IgG) in relation to age among non-vaccinated hepatitis A patients. There were statistically significantly more patients up to 45 years of age with anti-HAV IgG negative results than those over 45 years of age, and the Fi-square correlation coefficient (Φ2) was 0.263 between the analyzed variables. The data analysis shows that the number of people with specific IgG antibodies against hepatitis A increases with age. The risk of hepatitis A infection in people under 45 is high due to widespread seronegativity in this age group.

PL

Na przestrzeni ostatnich kilkudziesięciu lat zaobserwowano w Polsce stopniowy spadek zachorowań na wirusowe zapalenie wątroby typu A i zwiększenie populacji osób nieuodpornionych, zwłaszcza w grupie osób młodych. Celem pracy była ocena obecności swoistych przeciwciał anty-HAV IgG w zależności od wieku, wśród osób nie szczepionych przeciw wirusowemu zapaleniu wątroby typu A. Zaobserwowano statystycznie znamiennie więcej pacjentów do 45 roku życia z wynikiem anty-HAV IgG ujemnym niż badanych powyżej 45 roku życia, a współczynnik korelacji Fi-kwadrat (Φ2) wynosił 0,263 pomiędzy rozpatrywanymi zmiennymi. Z analizy danych wynika, że z wiekiem rośnie liczba osób posiadających swoiste przeciwciała przeciw wirusowi zapalenia wątroby typu A w klasie IgG. Ryzyko zakażenia wirusem zaplenia wątroby typu A u osób poniżej 45 roku życia jest wysokie ze względu na powszechną seronegatywność w tej grupie wiekowej.

Słowa kluczowe

EN

hepatitis A infection; anty-HAV IgG; seroprevalence

PL

wirusowe zapalenie wątroby typu A; anty-HAV IgG; seroprewalencja

• Wydawca: Polskie Towarzystwo Medycyny i Techniki Hiperbarycznej
• Czasopismo: Polish Hyperbaric Research
• Rocznik: 2021
• Tom: nr 3(76)
• Strony: 67--76
• Opis fizyczny: Bibliogr. 33 poz., rys., tab., wykr.

Twórcy

autor

Henrykowska Gabriela

• Epidemiology and Public Health Department, Medical University of Lodz, Poland

autor

Kotecka Kornelia

• Department of Infectious and the Digestive Tract Diseases, Department of Infectious and Liver Diseases, Medical University of Lodz. Dr. Wł. Bieganski Provincial Specialist Hospital, Poland

autor

Jabłkowska Aleksandra

• Department of Infectious and the Digestive Tract Diseases, Department of Infectious and Liver Diseases, Medical University of Lodz. Dr. Wł. Bieganski Provincial Specialist Hospital, Poland

autor

Buczyński Andrzej

• Epidemiology and Public Health Department, Medical University of Lodz, Poland

autor

Woźny Joanna

• Department of Infectious and the Digestive Tract Diseases, Department of Infectious and Liver Diseases, Medical University of Lodz. Dr. Wł. Bieganski Provincial Specialist Hospital, Poland

Bibliografia

• 1. World Health Organization. Hepatitis A Fact sheet No. 328. Available from: http://www.searo.who.int/thailand/factsheets/fs0030/en/ [Accessed: 31 July 2019];
• 2. Feinstone SM. History of the discovery of hepatitis A virus. Cold Spring Harbor Perspectives in Medicine. 2019;9(5):9-22;
• 3. Livni G, Plotkin S, Yuhas Y, Chodik G, Aloni H, Lerman Y, Ashkenazi S. Seroepidemiology of hepatitis A antibodies among children’s hospital staff. Pediatr Infect Dis J. 2002, 21(7): 618–622;
• 4. Kaslow, R. A., Stanberry, L. R., Duc, L. & James, W. Viral infections in humans: epidemiology and control. Vol. 5th edition, 2014, 417–38;
• 5. Lemon, S. M., Ott, J. J., Van Damme, P. & Shouval, D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. Journal of Hepatology. 2018, 68, 167–184, https://doi.org/10.1016/j.jhep.2017.08.034;
• 6. Franco E, Meleleo C, Serino L, et al. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol 2012;4:68;
• 7. Vaughan G, Goncalves Rossi LM, Forbi JC, et al. Hepatitis A virus: host interactions, molecular epidemiology and evolution. Infect Genet Evol 2014;21:227–43;
• 8. Trepo C. A brief history of hepatitis milestones. Liver International. 2014;34:29-37;
• 9. Jacobsen, K. H. & Wiersma, S. T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010, 28, 6653–6657, https://doi.org/10.1016/j.vaccine.2010.08.037;
• 10. Hepatitis A virus in the EU/EEA, 1975-2014. A systematic review of seroprevalence and incidence comprising European surveillance data and national vaccination recommendations. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-virus-eueea-1975-2014;
• 11. Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, et al. Comparative hepatitis A seroepidemiology in 10 European countries. Epidemiol Infect. 2012 Dec;140(12):2172-81;
• 12. Meldunki o zachorowaniach na choroby zakaźne, zakażeniach i zatruciach w Polsce Available from: http://wwwold.pzh.gov.pl/oldpage/epimeld/index_p.html#04;
• 13. Shouval D. The immunological basis for immunization series. In: Immunization Vaccines and Biologicals. Switzerland: World Health Organization Department of Immunization; 2010. p. 39;
• 14. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. International Journal of Health Geographics. 2011;10:57;
• 15. Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med. 2010;170(20):1811-8. https://doi.org/10.1001/archinternmed.2010.401;
• 16. Yun H, Lee HJ, Yoon Y, Kim K, Kim S, Shin MH, et al. Seroprevalence of hepatitis-antibodies in relation to social factors, a preliminary study. Osong Public Health and Research Perspectives. 2012;3(1):31-35;
• 17. Kiyohara T, Sato T, Totsuka A, Miyamura T, Ito T, Yoneyama T. Shifting Seroepidemiology of hepatitis A in Japan, 1973-2003. Microbiology and Immunology. 2007;51(2):185-191;
• 18. Lagarde E, Joussemet M, Lataillade J, Fabre G. Risk factors for hepatitis A infection in France: Drinking tap water may be of importance. European Journal of Epidemiology. 1995;11(2):145-148;
• 19. Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):707-15;
• 20. Magdzik W., Czarkowski M. Zmiany w endemiczności wirusowego zapalenia wątroby typu A (WZW A) w Polsce. Przegl Epidemiol 2004; 58: 355-60;
• 21. Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: A new concern for adults. The Journal of Infectious Diseases. 2015;212:176-182;
• 22. Klevens, R. M., Denniston, M. M., Jiles-Chapman, R. B. & Murphy, T. V. Decreasing immunity to hepatitis A virus infection among US adults: Findings from the National Health and Nutrition Examination Survey (NHANES), 1999–2012. Vaccine. 2015, 33, 6192–6198, https://doi.org/10.1016/j.vaccine.2015.10.009;
• 23. Koff RS. Hepatitis A. Lancet. 1998;351(9116):1643-9. https://doi.org/10.1016/S0140-6736(98)01304-X;
• 24. Gossner CM, Severi E, Danielsson N, Hutin Y, Coulombier D. Changing hepatitis A epidemiology in the European Union: new challenges and opportunities. Euro Surveill. 2015;20(16):21101. https://doi.org/10.2807/1560-7917.ES2015.20.16.21101;
• 25. Janaszek-Seydlitz W, Bucholc B, Wiatrzyk A. Poziom przeciwciał przeciwko wirusowemu zapaleniu watroby typu A u osób z terenu Warszawy (Prevalence of anti-HAV antibodies in Warsaw population). Przegl Epidemiol. 2007; 61(4): 675-682;
• 26. Bura M, et al. Seroprevalence of hepatitis A virus antibodies (anti-HAV) in adult inhibitants of Wielkopolska region, Poland – the role of simple demographic factors. Ann Agric Environ Med 2012;19 (4):738-741;
• 27. Polz-Dacewicz MA, Policzkiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection – a comparative study in Central Eastern Poland (1990-1999). Med Sci Monit. 2000; 6(5): 989-993;
• 28. Chlabicz S, Grzeszczuk A. Przewlekłe zapalenie watroby typu C a ryzyko zakazenia wirusem zapalenia watroby typu A (Chronic hepatitis C and risk for hepatitis A infection). Przegl Epidemiol. 2001; 55(3): 281-286;
• 29. Hendrickx, G. et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat 15(Suppl 2), 1–15, https://doi.org/10.1111/j.1365-2893.2008.01022.x (2008);
• 30. Kumbang J, Ejide S, Tedder RS, Ngui SL. Outbreak of hepatitis A in an extended family after importation by non-immune travellers. Epidemiol Infect. 2012;140(10):1813-20. https://doi.org/10.1017/S0950268811002561;
• 31. Fiore, A. E. Hepatitis A transmitted by Food. Food Safety 2004, 38;
• 32. Sane J, MacDonald E, Vold L, Gossner C, Severi E, on behalf of the International Outbreak Investigation Team. Multistate foodborne hepatitis A outbreak among European tourists returning from Egypt--need for reinforced vaccination recommendations, November 2012 to April 2013. Euro Surveill. 2015;20(4):21018. https://doi.org/10.2807/1560-7917;
• 33. Pedersini R, Marano C, De Moerlooze L, Chen L, Vietri J. HAV & HBV vaccination among travellers participating in the National Health and Wellness Survey in five European countries. Travel Med Infect Dis. 2016;14(3):221-32. https://doi.org/10.1016/j.tmaid.2016.03.008.